基于MVA的JYNNEOS猴痘疫苗在刚果民主共和国参与者队列中的血清学反应
本研究评估了刚果民主共和国医护人员队列接种两剂JYNNEOS疫苗后的血清学反应质量与持久性。结果显示疫苗在第二剂后约第42天诱导强烈的正痘病毒特异性抗体反应,无既往天花疫苗接种或暴露者基线抗体较低但抗体滴度倍数上升相似,两组均产生牛痘病毒和猴痘病毒中和抗体;总IgG和中和抗体滴度在2年时降至接近基线,但多数参与者仍IgG血清阳性。
要点
- JYNNEOS在刚果民主共和国医护人员中诱导强烈的正痘病毒特异性抗体反应,约第42天达峰。
- 无既往天花疫苗接种或暴露者基线抗体较低,但第42天抗体滴度倍数上升与有接种史者相似。
- 两组均产生牛痘病毒和猴痘病毒中和抗体;2年时总IgG和中和抗体滴度下降至接近基线,多数仍IgG血清阳性。
核心结论
- JYNNEOS疫苗接种在猴痘流行区刚果民主共和国医护人员队列中触发有效的正痘病毒中和抗体反应。
- 作者认为,使用JYNNEOS进行猴痘疫苗接种可能有助于减轻猴痘相关疾病和经济负担,并应对病毒活跃循环地区的潜在暴发。
研究设计与样本
- 研究评估了刚果民主共和国大型医护人员队列接种两剂JYNNEOS疫苗后的血清学反应质量与持久性。
主要发现
- JYNNEOS在参与者中诱导强烈的正痘病毒特异性抗体反应,约在第42天(第二剂后2周)达峰。
- 无既往天花疫苗接种或暴露的参与者基线抗体水平较低,但第42天抗体滴度倍数上升与有既往接种史者相似。
- 既往未接种和有接种史的参与者均产生牛痘病毒和猴痘病毒中和抗体。
- 总正痘病毒特异性IgG滴度和中和抗体滴度从峰值下降,至2年时接近基线水平,但多数参与者在2年时间点仍IgG血清阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The current worldwide monkepox outbreak has reaffirmed the continued threat monkeypox virus (MPXV) poses to public health. JYNNEOS, a Modified Vaccinia Ankara (MVA)-based live, non-replicating vaccine, was recently approved for monkeypox prevention for adults at high risk of MPXV infection in the United States. Although the safety and immunogenicity of JYNNEOS have been examined previously, the clinical cohorts studied largely derive from regions where MPXV does not typically circulate. In this study, we assess the quality and longevity of serological responses to two doses of JYNNEOS vaccine in a large cohort of healthcare workers from the Democratic Republic of Congo (DRC). We show that JYNNEOS elicits a strong orthopoxvirus (OPXV)-specific antibody response in participants that peaks around day 42, or 2 weeks after the second vaccine dose. Participants with no prior history of smallpox vaccination or exposure have lower baseline antibody levels, but experience a similar fold-rise in antibody titers by day 42 as those with a prior history of vaccination. Both previously naïve and vaccinated participants generate vaccinia virus and MPXV-neutralizing antibody in response to JYNNEOS vaccination. Finally, even though total OPXV-specific IgG titers and neutralizing antibody titers declined from their peak and returned close to baseline levels by the 2-year mark, most participants remain IgG seropositive at the 2-year timepoint. Taken together, our data demonstrates that JYNNEOS vaccination triggers potent OPXV neutralizing antibody responses in a cohort of healthcare workers in DRC, a monkeypox-endemic region. MPXV vaccination with JYNNEOS may help ameliorate the disease and economic burden associated with monkeypox and combat potential outbreaks in areas with active virus circulation.
引用
- Priyamvada L, Carson WC, Ortega E, et al. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo. Vaccine. 2022. PMID: 36344361. doi:10.1016/j.vaccine.2022.10.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。